BioNxt Solutions Prepares for Human Bioequivalence Study For MS
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment.
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish.
The Company plans to make further updates in the coming weeks regarding its bioequivalent study preparation and scheduling, as well integration of its research and development operations with Gen-Plus.
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals Files Interim Financial Statements for the Nine Months Ended October 31, 202530.12.2025 03:20:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / December 29, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the nine-month period ended October 31, 2025, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at October 31, 2025 of $36,602,553 Total cash as at October 31, 2025 of $1,643,422 Working capital deficiency as at October 31, 2025 of $1,746,454 Shareholder's equity as at October 31, 2025 of $33,030,843 During the nine months ended October 31, 2025, the Company incurred $1,046,223 in cost for exploration activities at the TBN project. Key activities of the Company's management team this quarter included the completion of the initial drilling of the first step-out exploration target within the Escape down-plunge area, resulting in a mineralized intersection 400m from the known resource.
EESystem Files for Preliminary Injunction to Block Unauthorized Use of Proprietary Wellness Technology29.12.2025 17:15:00 CET | Press release
Legal action seeks to halt Jason Shurka and The Light System, Inc. from misappropriating EES intellectual property LAS VEGAS, NV / ACCESS Newswire / December 29, 2025 / Energy Enhancement System, LLC (EES), a global provider of advanced wellness technology, has taken decisive legal action to protect its proprietary innovations and the integrity of its licensed network. On December 22, 2025, EES filed a Motion for Preliminary Injunction in the U.S. District Court for the District of Nevada. The motion seeks to immediately enjoin defendants Jason Shurka and The Light System, Inc., operating via thelightsystems.com and unifydhealing.com, with events and personal bio promoted on jasonshurka.com, from the unauthorized use of EES's intellectual property. This filing is a critical step in defending the authenticity of the EE System technology, which powers an extensive global network with thousands of installations worldwide. The motion is supported by detailed evidence alleging contractual b
Launch of the 8th Global Conference on Occupational Safety and Health (GOSH 8) in RIYADH, SA - 202628.12.2025 13:30:00 CET | Press release
RIYADH, SA / ACCESS Newswire / December 28, 2025 / His Excellency Eng. Ahmed bin Sulaiman Al‑Rajhi, Minister of Human Resources and Social Development and Chairman of the National Council for Occupational Safety and Health, announced the launch of the 8th Global Conference on Occupational Safety and Health (GOSH8), scheduled to be held in 2026 under the theme "Sustainable Safety for a Prosperous Future." The conference will take place from 27 to 29 April 2026 at the Hilton Hotel in Riyadh, Saudi Arabia. During the announcement, His Excellency also inaugurated the official website of the 8th Global Conference on Occupational Safety and Health, which enables specialists and interested participants to register for the conference and access full details, including key themes, topics, and accompanying activities. The conference continues to play a leading role as an international scientific platform, dedicated to exploring the future of occupational safety and health, discussing global labo
Loar Holdings Inc. Announced The Completion of its Acquisition of LMB Fans & Motors26.12.2025 14:00:00 CET | Press release
WHITE PLAINS, NEW YORK / ACCESS Newswire / December 26, 2025 / Loar Holdings Inc. (NYSE:LOAR) ("Loar," "we," "our," or "the Company") today announced the completion of its acquisition of LMB Fans & Motors ("LMB") for €367 million, plus the assumption of debt, paid in cash at closing. Founded more than 60 years ago, LMB is a global leader in designing and manufacturing customized, high-performance fans and motors. With decades of expertise and nearly 100% of its revenue derived from proprietary designs, LMB offers over 2,000 unique products, including fans, blowers, motors, and specialized rotating machines. Its fans and brushless motors are widely used across aerospace and defense platforms. LMB employs more than 75 team members worldwide, including those at its headquarters and manufacturing facility in Malemort-sur-Corrèze, France. The transaction was completed following clearance under the French foreign direct investment screening procedure by the Ministry of Economy and Finance. L
SK tes Announces Grand Opening of New Shannon Facility, Marking a Milestone for Sustainable Technology in Ireland22.12.2025 15:00:00 CET | Press release
SHANNON, IE / ACCESS Newswire / December 22, 2025 / SK tes, a global leader in secure technology lifecycle and IT asset disposition (ITAD) services, is delighted to announce the grand opening of its state-of-the-art facility in Shannon, County Clare. The opening event, to be held on Jan. 15, 2026, marks the culmination of a journey that began with the company's announcement in 2025 of its plans to establish a purpose-built facility in one of Ireland's fastest-growing technology regions. The grand opening will be hosted by Jin Mo Lee, SK tes Group CEO at SK tes and guest of honor, Minister Timmy Dooley will cut the ribbon to officially open the site. Minister Dooley, a Clare native, serves as Minister of State for Climate, Energy and the Environment. Minister Dooley's leadership in climate, energy, and environmental policy is especially relevant as Ireland continues to attract major global data center infrastructure and technology companies, while placing increased emphasis on sustainab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom